David Tanzer

David Tanzer

Company: OcuTerra

Job title: Chief Medical Officer


Integrin Approaches to Combat Ocular Neovascularization 2:30 pm

Pre-clinical and clinical studies have shown that several integrins, including αvβ3 are expressed in neovascular ocular tissue from patients with nAMD & DR/DME, making them an attractive alternative target for nAMD & DR/DME therapeutics This presentation will focus on novel integrin approaches as an alternative target for angiogenesis derived diseasesRead more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.